Demand for Antibody Therapy in Japan

Future Market Insights

Key Insight

The demand for antibody therapy in Japan is projected to grow from USD 17.5 billion in 2026 to USD 45.9 billion by 2036, at a CAGR of 10.1%. Monoclonal Antibodies will dominate with a 67.0% market share, while hospitals will lead the end user segment with a 58.0% share.

December 24, 2025

Anurag Sharma

250 Pages

Cite this Report

Demand for Antibody Therapy in Japan

https://www.futuremarketinsights.com/reports/japan-antibody-therapy-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Astellas Pharma Inc
Chugai Pharmaceutical Co. Ltd
Daiichi Sankyo Company
Ono Pharmaceutical Co. Ltd
Takeda Pharmaceutical Company Limited

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Demand for Antibody Therapy in Japan

Key Players

Similar Industry Reports